Using synthetic networks to detect prostate cancer biomarkers
Development of Synthetic Metabolic and Genetic Networks for the Detection of Urogenital Cancers
This study is testing a new way to find prostate cancer markers in blood and urine samples from men who might have the disease, using advanced technology to improve diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 2 sites (Montpellier, Hérault and 1 other locations) |
| Trial ID | NCT04518072 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze various biomarkers in blood and urine samples from men suspected of having prostate cancer. Researchers will engineer synthetic metabolic and genetic networks to enhance the detection of these biomarkers, utilizing a novel hybrid analogue/digital approach with bacterial and paper-based biosensors. The study will involve a comparative analysis of 250 samples to evaluate the effectiveness of this innovative diagnostic method. The goal is to improve decision-making in diagnosing prostate cancer through advanced biosensing techniques.
Who should consider this trial
Good fit: Ideal candidates include men over 18 who are undergoing evaluation for prostate disease or have a positive or negative PSA blood result.
Not a fit: Patients with current prostatic or urinary infections or those with a history of treatment for prostate cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and efficient diagnostics for prostate cancer, potentially improving patient outcomes.
How similar studies have performed: While the approach of using synthetic metabolic pathways for biosensing is novel, similar studies have shown promise in biomarker detection, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men aged over 18 * Informed, written consent of the patient for the biological collection * Subject affiliated to a French social security scheme or beneficiary of such a scheme Patients specific inclusion criteria : - Admitted to care prostate disease or suspicion of prostate cancer and with a positive or negative PSA blood result Controls specific inclusion criteria : - Man free from all prostate or bladder pathologies Exclusion Criteria: * Patient under legal protection * Persons deprived of their liberty, protected adults or vulnerable persons * Participants may withdraw their consent at any time and for any reason whatsoever without incurring any negative consequences without change in their usual care Controls specific non-inclusion criteria : * Patient with current prostatic or urinary infection * History of treatment for prostate cancer other than surveillance management
Where this trial is running
Montpellier, Hérault and 1 other locations
- University Hospital — Montpellier, Hérault, France (Active_not_recruiting)
- Clinique Beau Soleil — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: Jerome SOLASSOL, PHD
- Email: j-solassol@chu-montpellier.fr
- Phone: 04.67.33.58.76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.